Eleven Biotherapeutics Inc. (EBIO) Major Shareholder Ventures Fund Iv L.P Flagship Sells 53,917 Shares
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) major shareholder Ventures Fund Iv L.P Flagship sold 53,917 shares of Eleven Biotherapeutics stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $3.39, for a total value of $182,778.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Ventures Fund Iv L.P Flagship also recently made the following trade(s):
- On Wednesday, September 21st, Ventures Fund Iv L.P Flagship sold 322,723 shares of Eleven Biotherapeutics stock. The shares were sold at an average price of $3.75, for a total value of $1,210,211.25.
- On Monday, September 19th, Ventures Fund Iv L.P Flagship sold 9,700 shares of Eleven Biotherapeutics stock. The shares were sold at an average price of $3.31, for a total value of $32,107.00.
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) opened at 3.50 on Thursday. The stock’s market cap is $53.88 million. Eleven Biotherapeutics Inc. has a 12-month low of $0.25 and a 12-month high of $5.97. The company’s 50-day moving average price is $4.45 and its 200-day moving average price is $2.19.
Eleven Biotherapeutics (NASDAQ:EBIO) last announced its earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. Eleven Biotherapeutics had a negative net margin of 2,995.34% and a negative return on equity of 207.40%. On average, equities analysts expect that Eleven Biotherapeutics Inc. will post ($1.75) EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in EBIO. Sabby Management LLC boosted its position in shares of Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 1,019,943 shares during the last quarter. Flagship Ventures Fund 2007 L.P. bought a new stake in Eleven Biotherapeutics during the first quarter valued at approximately $610,000. Flagship Ventures Fund IV L.P. bought a new stake in Eleven Biotherapeutics during the first quarter valued at approximately $469,000. Bank of New York Mellon Corp boosted its stake in Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 7,846 shares in the last quarter. Finally, Flagship Ventures Fund IV General Partner LLC bought a new stake in Eleven Biotherapeutics during the second quarter valued at approximately $2,464,000. 24.81% of the stock is owned by institutional investors and hedge funds.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.